PHASE 2, OPEN-LABEL, ACTIVITY, PHARMACODYNAMIC, PHARMACOKINETIC, AND SAFETY STUDY OF PTC299 IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2

Ptc Therapeutics, Inc., South Plainfield NJ

Investigators